NASDAQ:NCNA NuCana (NCNA) Stock Price, News & Analysis $8.31 -0.41 (-4.70%) (As of 10:42 AM ET) Add Compare Share Share Today's Range$8.18▼$8.8250-Day Range$2.55▼$9.7052-Week Range$2.53▼$20.25Volume19,259 shsAverage Volume74,239 shsMarket Capitalization$21.96 millionP/E RatioN/ADividend YieldN/APrice Target$150.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get NuCana alerts: Email Address NuCana MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,620.2% Upside$150.00 Price TargetShort InterestHealthy2.44% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.49Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.79) to ($11.25) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.84 out of 5 starsMedical Sector387th out of 924 stocksPharmaceutical Preparations Industry173rd out of 426 stocks 3.5 Analyst's Opinion Consensus RatingNuCana has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNuCana has only been the subject of 1 research reports in the past 90 days.Read more about NuCana's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.44% of the float of NuCana has been sold short.Short Interest Ratio / Days to CoverNuCana has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NuCana has recently increased by 42.56%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNuCana does not currently pay a dividend.Dividend GrowthNuCana does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NCNA. Previous Next 1.9 News and Social Media Coverage News SentimentNuCana has a news sentiment score of -0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for NuCana this week, compared to 1 article on an average week.Search Interest8 people have searched for NCNA on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.MarketBeat Follows4 people have added NuCana to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NuCana insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of NuCana is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.00% of the stock of NuCana is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NuCana's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NuCana are expected to grow in the coming year, from ($11.79) to ($11.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NuCana is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NuCana is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNuCana has a P/B Ratio of 0.99. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about NuCana's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About NuCana Stock (NASDAQ:NCNA)NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.Read More NCNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NCNA Stock News HeadlinesAugust 21 at 11:16 AM | finance.yahoo.comWe're A Little Worried About NuCana's (NASDAQ:NCNA) Cash Burn RateAugust 21 at 3:14 AM | americanbankingnews.comNuCana (NASDAQ:NCNA) Stock Rating Reaffirmed by OppenheimerAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.August 15, 2024 | markets.businessinsider.comNCNA Stock Earnings: NuCana Beats EPS for Q2 2024August 15, 2024 | finanznachrichten.deNuCana plc: NuCana Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 15, 2024 | globenewswire.comNuCana Reports Second Quarter 2024 Financial Results and Provides Business UpdateMay 30, 2024 | globenewswire.comNuCana to Present at the Jefferies Global Healthcare ConferenceMay 21, 2024 | finance.yahoo.comNuCana to Present at TD Cowen’s 5th Annual Oncology Innovation SummitAugust 22, 2024 | Insiders Exposed (Ad)$5k to $1.3m in just 3 tradesIt doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.May 21, 2024 | globenewswire.comNuCana to Present at TD Cowen's 5th Annual Oncology Innovation SummitMay 16, 2024 | msn.comNCNA Stock Earnings: NuCana Beats EPS for Q1 2024May 16, 2024 | finanznachrichten.deNuCana plc: NuCana Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 16, 2024 | globenewswire.comNuCana Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 1, 2024 | globenewswire.comNuCana Regains Compliance with Nasdaq Minimum Bid Price RequirementApril 18, 2024 | finance.yahoo.comNuCana plc (NCNA)April 16, 2024 | finance.yahoo.comNuCana Announces Completion of ADS Ratio ChangeApril 9, 2024 | globenewswire.comNuCana Presents Data at the AACR 2024 Annual Meeting Highlighting the Ability of NUC-7738 to Profoundly Alter Tumor Biology in a Paired Biopsy Clinical StudyApril 5, 2024 | benzinga.comNuCana Stock (NASDAQ:NCNA), Quotes and News SummarySee More Headlines Receive NCNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/17/2021Today8/22/2024Next Earnings (Estimated)11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NCNA CUSIPN/A CIK1709626 Webwww.nucana.com Phone441313571111FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Stock Price Target$150.00 High Stock Price Target$150.00 Low Stock Price Target$150.00 Potential Upside/Downside+1,620.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($11.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-34,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-143.48% Return on Assets-83.22% Debt Debt-to-Equity RatioN/A Current Ratio1.53 Quick Ratio1.53 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.85 per share Price / Book0.99Miscellaneous Outstanding Shares2,643,000Free Float1,818,000Market Cap$23.05 million OptionableNot Optionable Beta0.99 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Hugh Stephen Griffith (Age 56)Founder, CEO & Executive Director Comp: $1.24MMr. Donald Munoz (Age 55)Chief Financial Officer Mr. David Harrison (Age 64)Head of Translational Medicine Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)M.D., Chief Medical Officer Ms. Theresa BruceSenior Vice President of Clinical OperationsMs. Elisabeth OelmannSenior Vice President of Medical & Clinical DevelopmentMartin QuinnCompany SecretaryMore ExecutivesKey CompetitorsInterCureNASDAQ:INCRAclaris TherapeuticsNASDAQ:ACRSJourney MedicalNASDAQ:DERMDBV TechnologiesNASDAQ:DBVTPowerUp AcquisitionNASDAQ:PWUPView All CompetitorsInstitutional OwnershipGlass Jacobson Investment Advisors llcBought 15,000 shares on 8/12/2024Ownership: 0.568%Carlyle Group Inc.Sold 3,200,000 shares on 8/9/2024Ownership: 5.045%Renaissance Technologies LLCSold 403,815 shares on 8/9/2024Ownership: 0.636%Acadian Asset Management LLCSold 567,027 shares on 8/6/2024Ownership: 0.895%Baillie Gifford & Co.Bought 146,360 shares on 7/25/2024Ownership: 5.544%View All Institutional Transactions NCNA Stock Analysis - Frequently Asked Questions How have NCNA shares performed this year? NuCana's stock was trading at $7.3950 at the beginning of the year. Since then, NCNA shares have increased by 17.9% and is now trading at $8.72. View the best growth stocks for 2024 here. How were NuCana's earnings last quarter? NuCana plc (NASDAQ:NCNA) released its quarterly earnings results on Wednesday, November, 17th. The company reported ($375.00) earnings per share for the quarter, beating analysts' consensus estimates of ($462.58) by $87.58. When did NuCana's stock split? NuCana's stock reverse split on the morning of Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did NuCana IPO? NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen served as the underwriters for the IPO and William Blair was co-manager. Who are NuCana's major shareholders? Top institutional investors of NuCana include Baillie Gifford & Co. (5.54%), Carlyle Group Inc. (5.04%), Acadian Asset Management LLC (0.89%) and Renaissance Technologies LLC (0.64%). How do I buy shares of NuCana? Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of NuCana own? Based on aggregate information from My MarketBeat watchlists, some other companies that NuCana investors own include Wirecard (WDI), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), Ovid Therapeutics (OVID), SCYNEXIS (SCYX), Aldeyra Therapeutics (ALDX) and Allena Pharmaceuticals (ALNA). This page (NASDAQ:NCNA) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NuCana plc Please log in to your account or sign up in order to add this asset to your watchlist. Share NuCana With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
